REID-PROVIDENT LABORATORIES INC. – Trademark Portfolio

Entity Type: 03

REID-PROVIDENT LABORATORIES INC. holds 44 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 44 filings in this category. The owner is based in ATLANTA, GA.

25 5TH ST. NW.

ATLANTA, GA 30308

44 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

MELFIAT
MELFIAT
Cancelled 1985
NAUTROL
NAUTROL
Cancelled 1985
AQUATAG
AQUATAG
Cancelled 1985
SPRX-3
SPRX-3
Cancelled 1985
NEOTEP
NEOTEP
Cancelled 1984
HYSERP
HYSERP
Cancelled 1984
COMPAL
COMPAL
Cancelled 1983
ZENATE
ZENATE
Cancelled 1982
UNIFAST
UNIFAST
Cancelled 1979
CURRETAB
CURRETAB
Cancelled 1978
TENAX
TENAX
Cancelled 1977
SUMOX
SUMOX
Cancelled 1976
EUGEL
EUGEL
Cancelled 1976
PROVIGAN
PROVIGAN
Cancelled 1976
VASOGLYN
VASOGLYN
Cancelled 1976
TRANMEP
TRANMEP
Cancelled 1976
MELFIAT
MELFIAT
Cancelled 1976

Page 1 of 2 (44 results)

Trademark Classifications

REID-PROVIDENT LABORATORIES INC.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (44 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does REID-PROVIDENT LABORATORIES INC. have?

REID-PROVIDENT LABORATORIES INC. has 44 U.S. trademarks filed with the USPTO.

What trademark classes does REID-PROVIDENT LABORATORIES INC. file in?

REID-PROVIDENT LABORATORIES INC. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What is REID-PROVIDENT LABORATORIES INC.'s trademark registration success rate?

REID-PROVIDENT LABORATORIES INC. has a 0% trademark registration rate, with 0 out of 44 resolved applications resulting in successful registration. Currently, 0 applications are pending review.